T2 or Not T2 in COPD: That is the Question

References

1. Riesco Miranda J.A. Calle Rubio M. Díaz Pérez D. López-Campos J.L. Trigueros Carrero J.A. Celli B. Efficacy and safety of single-inhaler triple therapy containing dual bronchodilator with corticosteroids compared to monotherapy, dual therapy, or open triple therapy in moderate/severe COPD: A systematic literature review. Arch. Bronconeumol. 2024 60 1 55 58 10.1016/j.arbres.2023.10.006 37985278
   [Google Scholar]
2. Faiz A. Wiersma V.R. Salzbrunn J.B. COPD patients display increased peripheral blood somatic mutations which associate with the prevalence of co-morbidities. Arch. Bronconeumol. 2024 60 2 119 121 10.1016/j.arbres.2023.12.011 38212182
   [Google Scholar]
3. Girón Matute W.I. Ji Z. de Miguel Díez J. Clinical trials in COPD: Future challenges. Arch. Bronconeumol. 2024 60 2 75 76 10.1016/j.arbres.2023.11.013 38061930
   [Google Scholar]
4. Ambrosino P. Marcuccio G. Raffio G. Endotyping chronic respiratory diseases: T2 inflammation in the united airways model. Life 2024 14 7 899 10.3390/life14070899 39063652
   [Google Scholar]
5. Cosío B.G. Pérez de Llano L. Lopez Viña A. Th-2 signature in chronic airway diseases: Towards the extinction of asthma−COPD overlap syndrome? Eur. Respir. J. 2017 49 5 1602397 10.1183/13993003.02397‑2016 28461299
   [Google Scholar]
6. Wu X. Deng Z. Wu F. Clinical characteristics and 2-year outcomes of chronic obstructive pulmonary disease patients with high blood eosinophil counts: A population-based prospective cohort study in china. Arch. Bronconeumol. 2024 60 7 402 409 10.1016/j.arbres.2024.03.029 38749856
   [Google Scholar]
7. Marcos P.J. López-Campos J.L. Shall we focus on the eosinophil to guide treatment with systemic corticosteroids during acute exacerbations of chronic obstructive pulmonary disease (COPD)? CON. Med. Sci. 2018 6 2 49 10.3390/medsci6020049 29890705
   [Google Scholar]
8. Criner G.J. Celli B.R. Brightling C.E. Benralizumab for the prevention of COPD exacerbations. N. Engl. J. Med. 2019 381 11 1023 1034 10.1056/NEJMoa1905248 31112385
   [Google Scholar]
9. Agusti A. Lopez-Campos J.L. Miravitlles M. Triple therapy and clinical control in b+ COPD patients: A pragmatic, prospective, randomized trial. Arch. Bronconeumol. 2024 60 7 417 422 10.1016/j.arbres.2024.04.008 38729884
   [Google Scholar]
10. Figueira-Gonçalves J.M. de Miguel-Díez J. Initial treatment in COPD patients. Do we take into account the severity of the exacerbation? Arch. Bronconeumol. 2024 60 1 65 66 10.1016/j.arbres.2023.10.011 37985279
    [Google Scholar]
11. Brightling C. Greening N. Airway inflammation in COPD: Progress to precision medicine. Eur. Respir. J. 2019 54 2 1900651 10.1183/13993003.00651‑2019 31073084
    [Google Scholar]
12. Pan C. He Z. Lin S. Yue J. Chen Z. Guan W. Clinical characteristics and outcomes of the phenotypes of COPD -bronchiectasis association. Arch. Bronconeumol. 2024 60 6 356 363 10.1016/j.arbres.2024.04.003 38714385
    [Google Scholar]
13. Soler-Cataluña J.J. Almagro P. Huerta A. González-Segura D. Cosío B.G. Clinical control criteria to determine disease control in patients with severe COPD: The CLAVE study. Int. J. Chron. Obstruct. Pulmon. Dis. 2021 16 137 146 10.2147/COPD.S285385 33531800
    [Google Scholar]
14. Lopez-Campos J.L. Alcázar Navarrete B. Soriano J. Determinants of medical prescriptions for COPD care: An analysis of the EPOCONSUL clinical audit. Int. J. Chron. Obstruct. Pulmon. Dis. 2018 13 2279 2288 10.2147/COPD.S160842 30100718
    [Google Scholar]
15. Magnussen H. Disse B. Rodriguez-Roisin R. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014 371 14 1285 1294 10.1056/NEJMoa1407154 25196117
    [Google Scholar]